Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Viracta Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
VIRX
Nasdaq
8731
https://www.viracta.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Viracta Therapeutics Inc
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Mar 7th, 2024 9:05 pm
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
- Feb 29th, 2024 1:00 pm
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 6th, 2024 9:05 pm
Viracta Therapeutics Provides Clinical Update and Outlook for 2024
- Jan 4th, 2024 1:00 pm
Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma
- Dec 12th, 2023 1:00 pm
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
- Dec 4th, 2023 1:30 pm
Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 9th, 2023 1:30 pm
Viracta Therapeutics to Present at Upcoming Investor Conferences
- Nov 7th, 2023 9:15 pm
Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers
- Oct 4th, 2023 11:00 am
Viracta Therapeutics to Host R&D Day on October 4, 2023
- Sep 5th, 2023 1:00 pm
Viracta Therapeutics Announces New Employment Inducement Grant
- Aug 18th, 2023 8:05 pm
Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- Aug 14th, 2023 12:00 pm
Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma
- Aug 8th, 2023 12:30 pm
Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer
- Aug 7th, 2023 11:30 am
Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)
- Jun 28th, 2023 12:00 pm
Viracta Therapeutics to Present at the Jefferies Healthcare Conference
- May 31st, 2023 8:15 pm
2 “Strong Buy” Penny Stocks With Over 400% Upside on the Horizon
- May 17th, 2023 1:50 pm
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
- May 11th, 2023 8:05 pm
Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates
- May 8th, 2023 8:05 pm
Viracta Therapeutics Announces Departure of Chief Medical Officer
- May 2nd, 2023 8:05 pm
Scroll